ClinicalTrials.gov
public full text
Public Domain
Open-Label, Safety Study of Lofexidine
The purpose of this Phase 3 open-label treatment study is to evaluate the safety and effectiveness of lofexidine at a clinically relevant dose to alleviate symptoms of acute withdrawal from any opioid, including methadone and buprenorphine. This study will take place in a variety of clinical scenarios, both in-clinic and outpatient settings.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 7#1364570
- Main Study of Lofexidine and Methadone Pharmacodynamic Interaction in Methadone Maintained Patients#1339377
- Lofexidine for Inpatient Opiate Detox#1161910
- Evaluation of Lofexidine for Treatment of Opiate Withdrawal - 10#1349899
- Comparison of Buprenorphine and Methadone - 3#969315
Record · ID 1444933
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive